Data J L, Willke R J, Barnes J R, DiRoma P J
The Upjohn Company, Kalamazoo, MI 49002, USA.
Psychopharmacol Bull. 1995;31(1):67-73.
Pharmacoeconomic research will be an increasingly important aspect of drug development as providers, third-party payers, and worldwide government health agencies use cost-effectiveness and quality-of-life data to assist in making decisions on optimal pharmaceutical treatment protocols, formulary listings, and reimbursement. It is in the best interest of pharmaceutical companies to have an established, well-integrated pharmacoeconomic research program that can respond to the dynamic health-care environment and proactively plan a program to optimize patient care. The new paradigm for pharmacoeconomic research will require establishment and successful management of many internal and external customer relationships. This article discusses one company's organization of these relationships and how they are integrated into the drug development process during each stage of the product life cycle.
随着医疗服务提供者、第三方支付方以及全球政府卫生机构利用成本效益和生活质量数据来协助制定有关最佳药物治疗方案、药品目录清单及报销的决策，药物经济学研究将在药物研发中变得愈发重要。制药公司建立一个成熟、整合良好的药物经济学研究项目，以应对动态的医疗保健环境并积极规划优化患者护理的项目，这符合其最大利益。药物经济学研究的新范式将需要建立并成功管理众多内部和外部客户关系。本文讨论了一家公司对这些关系的组织方式，以及它们如何在产品生命周期的每个阶段融入药物研发过程。
